CG Oncology, Inc. Common stock
CGONNASDAQ
Healthcare
Biotechnology
$67.48
+0.69(1.03%)
52W $15.59 – $68.64
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
$5.7BMkt Cap
$4MRev TTM
-$176MNI TTM
-31.2xP/E TTM
What Changed Recently
Fundamentals
How The Business Makes Money
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Industry Biotechnology
Analyst View
Company Profile
CIK0001991792
ISINUS1569441009
CUSIP156944100
Address400 Spectrum Center Drive, Irvine, DE, US
SEC EDGAR